{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:51:18Z","timestamp":1790164278766,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidsponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jisp.2016.11.001","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T09:46:04Z","timestamp":1505900764000},"page":"S57-S63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Quinacrine Suppresses Tumor Necrosis Factor-\u03b1 and IFN-\u03b1 in Dermatomyositis and\u00a0Cutaneous Lupus Erythematosus"],"prefix":"10.1016","volume":"18","author":[{"given":"Paul","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wysocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Zeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jisp.2016.11.001_bib1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.141.7.855","article-title":"Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study","volume":"141","author":"Ang","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2012.11.012","article-title":"Innate immune processes in lupus erythematosus","volume":"147","author":"Aringer","year":"2013","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jisp.2016.11.001_bib4","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jisp.2016.11.001_bib5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2340\/00015555-2031","article-title":"Mepacrine in recalcitrant cutaneous lupus erythematosus: old-fashioned or still useful?","volume":"95","author":"Benoit","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jisp.2016.11.001_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archderm.144.2.173","article-title":"The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus","volume":"144","author":"Bonilla-Martinez","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jisp.2016.11.001_bib8","doi-asserted-by":"crossref","first-page":"e67036","DOI":"10.1371\/journal.pone.0067036","article-title":"TLR7\/TLR8 activation restores defective cytokine secretion by myeloid dendritic cells but not by plasmacytoid dendritic cells in HIV-infected pregnant women and newborns","volume":"8","author":"Cardoso","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jisp.2016.11.001_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0961203308101714","article-title":"Treatment of lupus skin involvement with quinacrine and hydroxychloroquine","volume":"18","author":"Cavazzana","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jisp.2016.11.001_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","article-title":"Response to antimalarials in cutaneous lupus erythematosus: a prospective analysis","volume":"147","author":"Chang","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib12","first-page":"380","article-title":"Long-term use of antimalarial drugs in rheumatic diseases","volume":"30","author":"Jover","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","article-title":"New concepts in antimalarial use and mode of action in dermatology","volume":"20","author":"Kalia","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jisp.2016.11.001_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2010.02.008","article-title":"Quality of life in cutaneous lupus erythematosus","volume":"64","author":"Klein","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib15","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jisp.2016.11.001_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archdermatol.2008.594","article-title":"Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients","volume":"145","author":"Moghadam-Kia","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF02685895","article-title":"Dendritic cells and the immunopathogenesis of systemic lupus erythematosus","volume":"37","author":"Monrad","year":"2007","journal-title":"Immunologic research"},{"key":"10.1016\/j.jisp.2016.11.001_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cei.12445","article-title":"Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications","volume":"178","author":"Moran","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jisp.2016.11.001_bib20","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar3549","article-title":"TNF\u03b1 release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients","volume":"14","author":"Nabatian","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jisp.2016.11.001_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Annal Rheum Dis"},{"issue":"3","key":"10.1016\/j.jisp.2016.11.001_bib22","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jisp.2016.11.001_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/187152807783334300","article-title":"TLR7\/9 antagonists as therapeutics for immune-mediated inflammatory disorders","volume":"6","author":"Sun","year":"2007","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.jisp.2016.11.001_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.jisp.2016.11.001_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1191\/096120300678828082","article-title":"The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients","volume":"9","author":"Toubi","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.jisp.2016.11.001_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2133.2005.06786.x","article-title":"Evidence for a role of type I interferons in the pathogenesis of dermatomyositis","volume":"153","author":"Wenzel","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jisp.2016.11.001_bib27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.jisp.2016.11.001_bib28","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jisp.2016.11.001_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the Cutaneous Dermatomyositis Disease Area and Severity\u00a0Index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"}],"container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002416300776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002416300776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T23:33:55Z","timestamp":1538350435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1087002416300776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1087002416300776"],"URL":"https:\/\/doi.org\/10.1016\/j.jisp.2016.11.001","relation":{},"ISSN":["1087-0024"],"issn-type":[{"value":"1087-0024","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinacrine Suppresses Tumor Necrosis Factor-\u03b1 and IFN-\u03b1 in Dermatomyositis and\u00a0Cutaneous Lupus Erythematosus","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology Symposium Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jisp.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}